SEATTLE, Sept. 27, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Board of Directors has elected Arnold C. Hanish to serve on the Company's Board. Mr. Hanish has also been appointed to serve as Chairman of the Audit Committee.
"Arnie's substantial depth and breadth of financial experience in the pharmaceutical industry will serve Omeros well as we advance our products to commercialization," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "We are pleased to add Arnie to our Board and expect that he will prove to be a valuable addition to our team."
"I am impressed with Omeros' collection of late- and early-stage programs and its ability to drive the development of this deep pipeline through efficient use of capital," stated Arnold C. Hanish. "I look forward to working with management to capitalize on Omeros' multiple opportunities for success."
Mr. Hanish has over 40 years of experience in finance. He currently serves as vice president, chief accounting officer, at Eli Lilly and Company, a position he has held since 1994. Prior to his appointment as chief accounting officer, he held a number of senior financial positions at Eli Lilly. Before Eli Lilly, Mr. Hanish was with Arthur Young & Company (currently Ernst & Young) for nearly 14 years. Mr. Hanish is a member of the Standing Advisory Group of the Public Company Accounting Oversight Board (PCAOB). In addition, he is the immediate past chairperson of Financial Executives International's (FEI's) Committee on Corporate Reporting, a position he held from 2007 to 2010. Mr. Hanish earned his B.A. in accounting from the University of Cincinnati.About Omeros Corporation Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four clinical-stage development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV